ARQT
Price
$31.88
Change
+$3.06 (+10.62%)
Updated
Oct 19, 04:59 PM (EDT)
Capitalization
3.62B
10 days until earnings call
Intraday BUY SELL Signals
PTGX
Price
$134.52
Change
+$5.77 (+4.48%)
Updated
Oct 19, 04:59 PM (EDT)
Capitalization
8.33B
17 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ARQT vs PTGX

ARQT vs PTGX Comparison Chart in %
View a ticker or compare two or three
VS
ARQT vs. PTGX commentary
Oct 19, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARQT is a Hold and PTGX is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ARQT with price predictions
Oct 16, 2026

ARQT's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for ARQT turned positive on October 13, 2026. Looking at past instances where ARQT's MACD turned positive, the stock continued to rise in 41 of 45 cases over the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on ARQT as a result. In 73 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.

ARQT moved above its 50-day moving average on October 09, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for ARQT crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 83%.

Following a +11.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARQT advanced for three days, in 248 of 293 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

Bearish Trend Analysis

The 10-day RSI Indicator for ARQT moved out of overbought territory on October 16, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 similar instances where the indicator moved out of overbought territory. In 28 of the 32 cases, the stock moved lower in the following days. This puts the odds of a move lower at 88%.

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARQT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

ARQT broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for ARQT entered a downward trend on September 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 29 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. ARQT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 54 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 80 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARQT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (16.422) is normal, around the industry mean (2.835). ARQT's P/E Ratio (131.000) is considerably higher than the industry average of (-0.607). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.264) among similar stocks. P/S Ratio (7.435) is also within normal values, averaging (438.009).

A.I.Advisor
a Summary for PTGX with price predictions
Oct 16, 2026

PTGX's Indicator enters downward trend

The Aroon Indicator for PTGX entered a downward trend on October 05, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 191 similar instances where the Aroon Indicator formed such a pattern. In 148 of the 191 cases the stock moved lower. This puts the odds of a downward move at 77%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PTGX as a result. In 68 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 72%.

The Moving Average Convergence Divergence Histogram (MACD) for PTGX turned negative on October 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 37 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 73%.

PTGX moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for PTGX crossed bearishly below the 50-day moving average on September 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 7 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 58%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PTGX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.

Bullish Trend Analysis

The RSI Indicator entered the oversold zone -- be on the watch for PTGX's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

Following a +3.55% 3-day Advance, the price is estimated to grow further. Considering data from situations where PTGX advanced for three days, in 234 of 306 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

PTGX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 4 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron PE Growth Rating for this company is 40 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. PTGX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 59 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 97 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.900) is normal, around the industry mean (2.835). PTGX has a moderately high P/E Ratio (105.533) as compared to the industry average of (-0.607). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.264) among similar stocks. P/S Ratio (34.130) is also within normal values, averaging (438.009).

FUNDAMENTALS RATINGS
ARQT vs PTGX: Fundamental Ratings
ARQT
PTGX
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
99
Overvalued
97
Overvalued
PROFIT vs RISK RATING
1..100
804
SMR RATING
1..100
5459
PRICE GROWTH RATING
1..100
4044
P/E GROWTH RATING
1..100
2940
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PTGX's Valuation (97) in the Biotechnology industry is in the same range as ARQT (99) in the null industry. This means that PTGX’s stock grew similarly to ARQT’s over the last 12 months.

PTGX's Profit vs Risk Rating (4) in the Biotechnology industry is significantly better than the same rating for ARQT (80) in the null industry. This means that PTGX’s stock grew significantly faster than ARQT’s over the last 12 months.

ARQT's SMR Rating (54) in the null industry is in the same range as PTGX (59) in the Biotechnology industry. This means that ARQT’s stock grew similarly to PTGX’s over the last 12 months.

ARQT's Price Growth Rating (40) in the null industry is in the same range as PTGX (44) in the Biotechnology industry. This means that ARQT’s stock grew similarly to PTGX’s over the last 12 months.

ARQT's P/E Growth Rating (29) in the null industry is in the same range as PTGX (40) in the Biotechnology industry. This means that ARQT’s stock grew similarly to PTGX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARQTPTGX
RSI
ODDS (%)
Bearish Trend 4 days ago
88%
Bullish Trend 4 days ago
75%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
84%
Bullish Trend 4 days ago
82%
Momentum
ODDS (%)
Bullish Trend 4 days ago
85%
Bearish Trend 4 days ago
72%
MACD
ODDS (%)
Bullish Trend 4 days ago
90%
Bearish Trend 4 days ago
73%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
84%
Bearish Trend 4 days ago
75%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
86%
Bearish Trend 4 days ago
81%
Advances
ODDS (%)
Bullish Trend 5 days ago
85%
Bullish Trend 8 days ago
76%
Declines
ODDS (%)
Bearish Trend 7 days ago
87%
Bearish Trend 6 days ago
75%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
81%
Bullish Trend 4 days ago
85%
Aroon
ODDS (%)
Bearish Trend 4 days ago
81%
Bearish Trend 4 days ago
77%
COMPARISON
Comparison
Oct 19, 2026
Stock price -- (ARQT: $28.82 vs. PTGX: $128.75)
Brand notoriety: ARQT and PTGX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARQT: 70% vs. PTGX: 134%
Market capitalization -- ARQT: $3.62B vs. PTGX: $8.33B
ARQT [@Biotechnology] is valued at $3.62B. PTGX’s [@Biotechnology] market capitalization is $8.33B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $126.66B. The average market capitalization across the [@Biotechnology] industry is $2.06B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARQT’s FA Score shows that 1 FA rating(s) are green while PTGX’s FA Score has 1 green FA rating(s).

  • ARQT’s FA Score: 1 green, 4 red.
  • PTGX’s FA Score: 1 green, 4 red.
According to our system of comparison, PTGX is a better buy in the long-term than ARQT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARQT’s TA Score shows that 5 TA indicator(s) are bullish while PTGX’s TA Score has 4 bullish TA indicator(s).

  • ARQT’s TA Score: 5 bullish, 5 bearish.
  • PTGX’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, ARQT is a better buy in the short-term than PTGX.

Price Growth

ARQT (@Biotechnology) experienced а +8.43% price change this week, while PTGX (@Biotechnology) price change was -10.42% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -7.77%. For the same industry, the average monthly price growth was -18.56%, and the average quarterly price growth was -19.45%.

Reported Earning Dates

ARQT is expected to report earnings on Oct 29, 2026.

PTGX is expected to report earnings on Nov 05, 2026.

Industries' Descriptions

@Biotechnology (-7.77% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
ARQT
Daily Signal:
Gain/Loss:
PTGX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
PXJ43.900.40
+0.92%
Invesco Oil & Gas Services ETF (PXJ)
HDEF33.790.25
+0.75%
Xtrackers MSCI EAFE High Dividend Yield Equity ETF (HDEF)
MYHC24.42-0.07
-0.28%
State Street My2029 High Yield Corporate Bond ETF (MYHC)
PBEU32.24-0.13
-0.40%
Portfolio Building Block European Banks Index ETF (PBEU)
NOVZ47.53-0.30
-0.63%
TrueShares Structured Outcome (November) ETF (NOVZ)

PTGX and

Correlation & Price change

A.I.dvisor indicates that over the last year, PTGX has been loosely correlated with DNTH. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if PTGX jumps, then DNTH could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PTGX
1D Price
Change %
PTGX100%
-5.71%
DNTH - PTGX
45%
Loosely correlated
-3.27%
PTCT - PTGX
45%
Loosely correlated
-2.87%
ARQT - PTGX
45%
Loosely correlated
-0.96%
PCVX - PTGX
44%
Loosely correlated
-2.53%
XNCR - PTGX
43%
Loosely correlated
-4.79%
More